<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>7938822</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Mataix, R</dc:author>
<dc:author>Jiménez, S</dc:author>
<dc:author>Malcorra, J J</dc:author>
<dc:author>Campo, C</dc:author>
<dc:author>Gómez Casares, M T</dc:author>
<dc:author>Pérez, M C</dc:author>
<dc:description xml:lang="en">Bone marrow aplasia remains the most serious adverse effect with gold therapy. Its prevalence is still a controversial issue and at present it is not possible to give accurate figures on its frequency. Two patients diagnosed of rheumatoid arthritis are reported. They underwent chrysotherapy and developed bone marrow aplasia within a 2-month period of therapy. The pathogenic mechanism of blood dyscrasias secondary to gold salts is still unknown. The best available method in the prevention of this serious condition is the periodical obtention of complete blood counts.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1994 Jul </dc:date>
<dc:title xml:lang="es">Aplasia medular y sales de oro. Actualización de la literatura a propósito de dos casos.</dc:title>
<dc:title xml:lang="en">[Bone marrow aplasia and gold salts. Review of the literature apropos of 2 cases].</dc:title>
<dc:publisher>Revista clinica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
